Contrasting Curaleaf (OTCMKTS:CURLF) & Rockwell Medical (NASDAQ:RMTI)

Rockwell Medical (NASDAQ:RMTI) and Curaleaf (OTCMKTS:CURLF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Valuation & Earnings

This table compares Rockwell Medical and Curaleaf”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$69.26 million	0.38	-$5.31 million	($1.50)	-4.42
Curaleaf	$1.27 billion	1.70	-$231.07 million	($0.39)	-23.72

Rockwell Medical has higher earnings, but lower revenue than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Rockwell Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rockwell Medical has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Curaleaf has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

Institutional & Insider Ownership

23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 0.0% of Curaleaf shares are owned by institutional investors. 4.6% of Rockwell Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Rockwell Medical and Curaleaf’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.98%	-15.41%	-9.62%
Curaleaf	-7.76%	-8.11%	-2.36%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rockwell Medical and Curaleaf, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	1	0	1	0	2.00
Curaleaf	0	0	1	3	3.75

Rockwell Medical presently has a consensus price target of $20.00, suggesting a potential upside of 201.66%. Given Rockwell Medical’s higher possible upside, analysts plainly believe Rockwell Medical is more favorable than Curaleaf.

Summary

Curaleaf beats Rockwell Medical on 8 of the 14 factors compared between the two stocks.

About Rockwell Medical

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.